Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study

British Medical Journal

Volumn 333, Issue 7561, 2006, Pages 224-227

  Tiihonen, Jari ^a   Wahlbeck, Kristian ^b   Lönnqvist, Jouko ^b   Klaukka, Timo ^c   Ioannidis, John P A ^d   Volavka, Jan ^e   Haukka, Jari ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

^d UNIVERSITY OF IOANNINA   (Greece)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROTHIXENE; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; THIORIDAZINE;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; COMMUNITY CARE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; FEMALE; FINLAND; FOLLOW UP; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDE; LENGTH OF STAY; MENTAL HEALTH SERVICE; PROSPECTIVE STUDY; PSYCHOSIS; STATISTICS; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; COMMUNITY MENTAL HEALTH SERVICES; FEMALE; FINLAND; HUMANS; LENGTH OF STAY; MALE; PATIENT READMISSION; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 33747185865     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38881.382755.2F     Document Type: Article

References (8)

1. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317;1181-4.
2. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
3. Geddes JR, Freemantle N, Harrison P, Bebbington PE. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
4. Geddes J. Prevention of relapse in schizophrenia. N Engl J Med 2002;346:56-8.
5. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9.
6. Isohanni M, Makikyro T, Moring J, Rasanen P, Hakko H, Partanen U, et al. A comparison of clinical and research DSM-III-R diagnoses of schizophrenia in a Finnish national birth cohort. Clinical and research diagnoses of schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1997;32:303-8.
7. Suvisaari JM, Haukka JK, Tanskanen AJ, Lönnqvist JK. Decline in the incidence of schizophrenia in Finnish cohorts born from 1954 to 1965. Arch Gen Psychiatry 1999;56:733-40.
8. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.